Clene reports Q2 net loss of $25.1M; ALS NfL biomarker positive; cash $49.2M

Clene Inc.

Net loss of $25.1M ($0.29 per share) versus $4.5M loss in Q2 2022; R&D down to $6.6M.
Cash, equivalents and marketable securities $49.2M after $40M June public offering; potential $130M more from warrants.
CNM-Au8 reduced plasma neurofilament light chain (NfL) vs placebo (p=0.04) in HEALEY ALS trial at 24 weeks.
Phase 2 RESCUE ALS results published in Lancet eClinicalMedicine; preparing for FDA ALS regulatory meetings.
NMSS grant funds Cohort 2 of REPAIR-MS for progressive MS; multiple near-term data announcements expected.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Clene Inc. reported second quarter 2023 results: net income $25.1 million, EPS $0.29 per share.

Period: second quarter 2023
Net income: $25.1 million
EPS: $0.29 per share
Result: reported results

Exact text from the filing

Clene reported a net loss of $25.1 million , or $0.29 per share, for the quarter ended June 30, 2023

View on SEC.gov

Browse all earnings releases →

Clene Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-023415

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.